Exploring Undertreatment of Psoriasis in Skin of Color

Panelists discuss how undertreatment remains pervasive in psoriasis management, with recent data from Gondo (2024) revealing that nearly one-third of patients with moderate to severe disease receive only over the counter (OTC), complementary, or topical therapies, while similarly high percentages of patients with mild disease but high-impact location involvement are undertreated, with disparities particularly affecting patients of color, those of lower socioeconomic status, and individuals whose limited body surface area (BSA) involvement in sensitive or visible areas significantly impacts their quality of life despite not meeting traditional severity thresholds.